S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
NASDAQ:MNKD

MannKind (MNKD) Stock Forecast, Price & News

$4.32
0.00 (0.00%)
(As of 06/6/2023 ET)
Compare
Today's Range
$4.26
$4.44
50-Day Range
$3.72
$4.79
52-Week Range
$2.91
$5.73
Volume
2.27 million shs
Average Volume
3.20 million shs
Market Capitalization
$1.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

MannKind MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
50.5% Upside
$6.50 Price Target
Short Interest
Bearish
14.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.14mentions of MannKind in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.84 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.14) to $0.11 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

752nd out of 981 stocks

Pharmaceutical Preparations Industry

364th out of 464 stocks


MNKD stock logo

About MannKind (NASDAQ:MNKD) Stock

MannKind Corp. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic products and devices for those with endocrine and orphan lung diseases. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Receive MNKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.

MNKD Stock News Headlines

MannKind Co. (NASDAQ:MNKD) CEO Sells $45,300.00 in Stock
MannKind (NASDAQ:MNKD) Trading Up 3.2%
NOTICE: Your retirement is in immediate danger
Soon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>
MannKind (NASDAQ: MNKD)
MannKind Co. (NASDAQ:MNKD) CFO Sells $223,272.70 in Stock
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
MannKind (NASDAQ:MNKD) Upgraded to Buy by StockNews.com
RBC Capital Keeps Their Hold Rating on MannKind (MNKD)
MannKind: Q1 Earnings Snapshot
MannKind Corp. Q1 Loss decreases, beats estimates
Why Shares of MannKind Are Up Wednesday
MannKind (MNKD) Q1 2023 Earnings Call Transcript
MannKind (MNKD) to Release Earnings on Tuesday
See More Headlines

MNKD Price History

MNKD Company Calendar

Last Earnings
5/09/2023
Today
6/06/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MNKD
CUSIP
56400P20
Employees
348
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$6.50
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+51.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-87,400,000.00
Pretax Margin
-55.45%

Debt

Sales & Book Value

Annual Sales
$99.77 million
Book Value
($0.95) per share

Miscellaneous

Free Float
253,734,000
Market Cap
$1.14 billion
Optionable
Optionable
Beta
1.56

Social Links


Key Executives

  • Michael E. CastagnaMichael E. Castagna
    Chief Executive Officer & Director
  • Lauren M. Sabella
    Chief Operating Officer & Executive Vice President
  • Steven B. BinderSteven B. Binder
    Chief Financial Officer
  • Joseph Kocinsky
    Chief Technology Officer
  • Kevin Kaiserman
    Vice President-Medical Affairs & Safety













MNKD Stock - Frequently Asked Questions

Should I buy or sell MannKind stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MNKD shares.
View MNKD analyst ratings
or view top-rated stocks.

What is MannKind's stock price forecast for 2023?

1 equities research analysts have issued twelve-month price targets for MannKind's stock. Their MNKD share price forecasts range from $6.00 to $7.00. On average, they predict the company's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 51.2% from the stock's current price.
View analysts price targets for MNKD
or view top-rated stocks among Wall Street analysts.

How have MNKD shares performed in 2023?

MannKind's stock was trading at $5.27 at the start of the year. Since then, MNKD stock has decreased by 18.4% and is now trading at $4.30.
View the best growth stocks for 2023 here
.

When is MannKind's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our MNKD earnings forecast
.

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) posted its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. The biopharmaceutical company earned $40.63 million during the quarter, compared to the consensus estimate of $37.40 million. The business's revenue for the quarter was up 238.8% on a year-over-year basis. During the same period last year, the firm earned ($0.10) EPS.

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

Who are MannKind's major shareholders?

MannKind's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.83%), State Street Corp (6.77%), Davidson Kempner Capital Management LP (0.00%), Geode Capital Management LLC (1.95%), Emerald Advisers LLC (1.38%) and Two Sigma Investments LP (1.16%). Insiders that own company stock include Alejandro Galindo, Anthony C Hooper, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross.
View institutional ownership trends
.

How do I buy shares of MannKind?

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $4.30.

How much money does MannKind make?

MannKind (NASDAQ:MNKD) has a market capitalization of $1.14 billion and generates $99.77 million in revenue each year. The biopharmaceutical company earns $-87,400,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.

How many employees does MannKind have?

The company employs 348 workers across the globe.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The official website for the company is www.mannkindcorp.com. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at ir@mannkindcorp.com, or via fax at 661-775-2081.

This page (NASDAQ:MNKD) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -